You are here

Phase III Data Presented for Vitrase in the Treatment of Vitreous Hemorrhage

IRVINE, Calif., Aug. 21 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (NASDAQ:ISTA) today announced that the Company presented integrated results from two Phase III clinical trials of Vitrase(R) (ovine hyaluronidase) for the treatment of vitreous hemorrhage, a serious condition affecting the back of the eye for which there is currently no drug treatment. The presentation was made at this week's 21st Annual Meeting of the American Society of Retina Specialists in New York.

The integrated results demonstrated a statistically significant reduction in vitreous hemorrhage density as early as one month and through three months following a single intravitreous injection of Vitrase when compared to a single injection of saline solution. This reduction allows the investigator to see into the back of the eye and diagnose the underlying cause of the hemorrhage. These clinical results were previously submitted to the U.S. Food & Drug Administration as part of the Company's New Drug Application (NDA) for Vitrase for vitreous hemorrhage and were announced last year.

ISTA's Vitrase is a proprietary formulation of highly purified ovine hyaluronidase, which has been studied for administration by injection into the vitreous of the eye.

On August 5th, 2003, ISTA submitted a second NDA seeking approval for use of Vitrase as a spreading agent to facilitate the dispersion and absorption of other drugs. In addition, in the Dosage and Administration section of the NDA, the Company is seeking approval from the FDA to provide directions for reconstitution of Vitrase for potential treatment applications in the back of the eye.

ISTA is a specialty pharmaceutical company focused on the development and commercialization of unique and uniquely improved ophthalmic products. ISTA's product candidates and programs seek to address serious diseases and conditions of the eye such as vitreous hemorrhage, diabetic retinopathy, hyphema, glaucoma, ocular pain and inflammation. Building on this pipeline, ISTA's goal is to become a fully integrated specialty pharmaceutical company by acquiring complementary products, either already marketed or in late-stage development.

Source: ISTA Pharmaceuticals, Inc.

Recent Headlines

Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology
Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission